
The meeting, which comes a year after the agency issued a complete response letter in October 2025,2 was held from 8:30 am-3 pm ET and was open to public.
FDA advisers review SYD-101, low-dose atropine 0.01% for pediatric myopia, on Oct 30 after a 2025 complete response letter.
The US FDA Dermatologic and Ophthalmic Drugs Advisory Committee will meet October 30, 2026, to review new drug application (NDA) 219694 for SYD-101 (atropine sulfate ophthalmic solution 0.01%; Sydnexis), proposed for slowing myopia progression in children aged 3 years or older.1





